Compare ODC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | ARVN |
|---|---|---|
| Founded | 1941 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.7M | 781.0M |
| IPO Year | 1994 | 2018 |
| Metric | ODC | ARVN |
|---|---|---|
| Price | $67.81 | $11.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $15.35 |
| AVG Volume (30 Days) | 50.2K | ★ 786.6K |
| Earning Date | 03-11-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | 50.45 | ★ 58.84 |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $485,572,000.00 | $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.98 | ★ N/A |
| Revenue Growth | ★ 10.97 | N/A |
| 52 Week Low | $41.37 | $5.90 |
| 52 Week High | $70.01 | $14.22 |
| Indicator | ODC | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 66.29 | 47.06 |
| Support Level | $58.40 | $11.07 |
| Resistance Level | $69.80 | $12.62 |
| Average True Range (ATR) | 1.85 | 0.66 |
| MACD | 0.54 | 0.03 |
| Stochastic Oscillator | 93.59 | 53.97 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.